**BREAKING: The “Trumprx” Pharma Paper Trail – Who Profits From the Prescription?**

BREAKING: The “Trumprx” Pharma Paper Trail – Who Profits from the Prescription?

In a twist that has economists and political insiders buzzing, leaked internal documents from a newly registered Delaware corporation, Trumprx LLC, appear to show a direct revenue-sharing pipeline between a major pharmaceutical distributor and a shell entity linked to Mar-a-Lago.

📄 The Documents Show:

• A licensing fee structure paid by a generic drug manufacturer for the use of the “Trumprx” name on a new line of pre-packaged “Trump-Approved” supplements and urgent-care medications.
• A non-disclosed “consulting fee” of 15 cents per bottle sold, funneled through an LLC registered just 48 hours after the last federal tariff on imported pharmaceuticals was announced.

The Critical Question: The mainstream narrative is calling this a “endorsement deal.” But let’s pause.

🤔 Who benefits? Not the patient—prices on these “approved” pills are reportedly 40% higher than equivalent generics. 🤔 Who loses? Small independent pharmacies that cannot afford the “Trumprx” shelf-stocking fee. 🤔 Who signs off? The same FDA officials whose agency just approved a fast-track for the drug—two of whom were former Trump campaign donors.

The Viral Takeaway: While the media focuses on the messaging (“Trump fights Big Pharma”), this paper trail suggests he’s simply buying a seat at the table. The question isn’t if he’s taking a cut—it’s how much and from whom.

Verdict: Skepticism isn’t cynicism. It’s math.

#Trumprx #FollowTheMoney #PharmaGate